[
  {
    "id": 1,
    "age": 56,
    "sex": "",
    "diagnosis": "Lung Adenocarcinoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "KRAS p.G13D Mutation",
      "TP53 p.A276G Mutation",
      "PTPRS R238* Mutation",
      "ZFHX3 p.F2994L Mutation",
      "CDH1 p.D433 Mutation"
    ],
    "tumor_pathogenic": [
      "KRAS p.G13D Mutation",
      "TP53 p.A276G Mutation"
    ],
    "mtb_recommendations":{
      "KRAS p.G13D Mutation": "Based on the tumor profile, no definitive treatment recommendation can be offered.",
      "TP53 p.A276G Mutation": "No treatment recommendation"
    }
  },
  {
    "id": 2,
    "age": 26,
    "sex": "",
    "diagnosis": "Urachal Carcinoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "KRAS p.G12V Mutation",
      "BCORL p.R1332* Mutation",
      "TP53 p.H214fs*7 Mutation",
      "CDKN2C p.L65F Mutation",
      "MAP3K1 p.T949_E950insT Mutation",
      "MYCN p.E47fs*8 Mutation",
      "CTNNA1 p.K577_L578 > TKL Mutation",
      "JAK1 p.I597M Mutation",
      "FANCL p.T367fs*12+ Mutation",
      "PIK3CA amplification (n>6)",
      "MYC amplification (n>6)",
      "MYCL1 amplification (n>6)",
      "SOX2 amplification (n>6)",
      "MUTYH amplification (n>6)"
    ],
    "tumor_pathogenic": [
      "KRAS p.G12V Mutation",
      "TP53 p.H214fs*7 Mutation",
      "MYCN p.E47fs*8 Mutation",
      "PIK3CA amplification (n>6)",
      "MYC amplification (n>6)",
      "MYCL1 amplification (n>6)",
      "SOX2 amplification (n>6)",
      "MUTYH amplification (n>6)"
    ],
    "mtb_recommendations": {
      "KRAS p.G12V Mutation": "Everolimus",
      "TP53 p.H214fs*7 Mutation": "No treatment recommendation",
      "MYCN p.E47fs*8 Mutation": "No treatment recommendation",
      "PIK3CA amplification (n>6)": "Everolimus",
      "MYC amplification (n>6)": "No treatment recommendation",
      "MYCL1 amplification (n>6)": "No treatment recommendation",
      "SOX2 amplification (n>6)": "No treatment recommendation",
      "MUTYH amplification (n>6)": "No treatment recommendation"
    }
  },
  {
    "id": 3,
    "age": 58,
    "sex": "",
    "diagnosis": "Thymic adenomcarcinoma",
    "stage": "IV",
    "type": "Whole-Exome",
    "germline_alteration": [
      "BRCA2 p.K3326* (1N)"
    ],
    "tumor_alteration": [
      "SMAD4 p.C363R (1N) Mutation",
      "TP53 p.305fs (2N_LOH) Mutation",
      "CDKN1B p.K100N (2N_LOH) Mutation",
      "ATM p.E1666* (4N) Mutation",
      "MAP3K8 p.H236Y (1N) Mutation",
      "TRAF1 p.R70H (2N) Mutation",
      "HDAC2 p.R409* (1N) Mutation",
      "TMEM111-TDRD3 fusion",
      "PRKDC-CDH17 fusion",
      "EXT1-MAGI2 fusion",
      "ERBB2 RNA overexpression (RPKM tumor 45 v 1.8 control)",
      "ERBB3 RNA overexpression (RPKM tumor 65.9 v 0.2 control)",
      "PDGFRB RNA overexpression (RPKM tumor 35.8 vs 2.3 control)",
      "TGFA RNA overexpression (RPKM tumor 14.2 v 0.4 control",
      "EGF RNA overexpression (RPKM tumor 1.9 vs 0.1 control)",
      "FGFR3 RNA overexpression (RPKM tumor 11.4 vs 1.9 control)",
      "MET RNA overexpression (RPKM tumor 22.1 v 1.4 control)"
    ],
    "tumor_pathogenic": [
      "SMAD4 p.C363R (1N) Mutation",
      "ATM p.E1666* (4N) Mutation",
      "PRKDC-CDH17 fusion",
      "EXT1-MAGI2 fusion",
      "ERBB2 amplification",
      "ERBB3 amplification",
      "PDGFRB amplification",
      "TGFA amplification",
      "EGF amplification",
      "FGFR3 amplification",
      "MET amplification"
    ],
    "mtb_recommendations": {
      "SMAD4 p.C363R (1N) Mutation": "No treatment recommendation",
      "ATM p.E1666* (4N) Mutation": "Perform HRD testing to determine if PARP inhibitors are appropriate, and then add them to the treatment regimen if the patient has not progressed on platinum-based chemotherapy.",
      "PRKDC-CDH17 fusion":"No treatment recommendation",
      "EXT1-MAGI2 fusion": "No treatment recommendation",
      "ERBB2 amplification": "HER2 inhibition with trastuzumab deruxtecan, additional HER2-IHC recommended (evidence level at least m2A, DESTINY-04)",
      "ERBB3 amplification":"No treatment recommendation",
      "PDGFRB amplification":"No treatment recommendation",
      "TGFA amplification":"No treatment recommendation",
      "EGF amplification":"No treatment recommendation",
      "FGFR3 amplification": "Futibatinib (PMID 34551969), m2B",
      "MET amplification": "Conduct cMET immunohistochemistry (IHC) to assess cMET expression and consider telisotuzumab vedotin (or alternatively, capmatinib)"
    }
  },
  {
    "id": 4,
    "age": 59,
    "sex": "",
    "diagnosis": "Loropharyngeal carcinoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "PIK3CA p.E545K Mutation (AF 25%)",
      "MAPK1 p.E322K Mutation (AF 10%)",
      "FGFR3 p.D786N Mutation (AF 30%)"
    ],
    "tumor_pathogenic": [
      "PIK3CA p.E545K Mutation (AF 25%)",
      "MAPK1 p.E322K Mutation (AF 10%)"
    ],
    "mtb_recommendations": {
      "PIK3CA p.E545K Mutation (AF 25%)":"Inclusion in the CRAFT trial (NCT04551521) after failing chemotherapy treatment and alpelisib (PIK3CA inhibitor), PMID: 29401002, PMID: 31091374, PMID: 35133871.",
      "MAPK1 p.E322K Mutation (AF 10%)":"No treatment recommendation"
    }
  },
  {
    "id": 5,
    "age": 64,
    "sex": "f",
    "diagnosis": "Lung Adenocarcinoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "EGFR p.E746_A750del Mutation (AF 43%)",
      "TP53 p.A138_Q144del Mutation (AF 37%)",
      "MET Amplification FISH positive"
    ],
    "tmb": "TMB 3.8 Mut/Mb",
    "tumor_pathogenic": [
      "EGFR Mutation"
    ],
    "mtb_recommendations": {
      "EGFR Mutation":"MET amplification is a potential secondary resistance mechanism in EGFR-inhibitor treated patients. If no EGFR inhibitors have been used, consider EGFR inhibition based on the level of MET amplification and clinical progression. However, if resistance is mediated by MET, use EGFR inhibitors with caution (PMID: 34837746)."
    }
  },
  {
    "id": 6,
    "age": 59,
    "sex": "m",
    "diagnosis": "Lung Adenocarcinoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "KRAS p.G12C Mutation (AF 18%)",
      "KEAP1 p.L276F Mutation (AF 45%)",
      "STK11 p.K83Tfs*13 Mutation (AF 38%)"
    ],
    "tumor_pathogenic": [
      "KRAS p.G12C Mutation (AF 18%)"
    ],
    "mtb_recommendations": {
      "KRAS p.G12C Mutation (AF 18%)":"Sotorasib, approved second-line treatment for lung cancer, source: DOI: 10.1056/NEJMoa2103695. Study check nNGM, e.g. KontRASt-01 & -03 (JGQ)"
    }
  },
  {
    "id": 7,
    "age": 41,
    "sex": "f",
    "diagnosis": "Melanoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "TMB 12.8 Mut/Mb",
      "NF1 p.I1605fs Mutation (AF 39%)",
      "TP53 c.672+1G>A Mutation (AF 50%)",
      "RB1 p.Q846* Mutation (AF 20%)",
      "TERT p.R859Q Mutation (AF 41%)"
    ],
    "tumor_pathogenic": [
      "TMB Tumor Mutational Burden 12.8 Mut/Mb",
      "NF1 p.I1605fs Mutation (AF 39%)",
      "TP53 c.672+1G>A Mutation (AF 50%)"
    ],
    "mtb_recommendations": {
      "TMB Tumor Mutational Burden 12.8 Mut/Mb":"No treatment recommendation",
      "NF1 p.I1605fs Mutation (AF 39%)":"CR: MEK inhibition with trametinib in NF1 mutated melanoma, PR, m1C, doi: 10.1200/PO.18.00028",
      "TP53 c.672+1G>A Mutation (AF 50%)":"No treatment recommendation"
    }
  },
  {
    "id": 8,
    "age": 46,
    "sex": "m",
    "diagnosis": "Cholangiocarcinoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "TMB 1.2 Mut/Mb",
      "FGFR2::BICC1 Fusion",
      "TP53 p.E258* Mutation (AF 52%)"
    ],
    "tumor_pathogenic": [
      "TMB Tumor Mutational Burden 1.2 Mut/Mb",
      "FGFR2::BICC1 Fusion",
      "TP53 p.E258* Mutation (AF 52%)"
    ],
    "mtb_recommendations": {
      "TMB Tumor Mutational Burden 1.2 Mut/Mb":"No treatment recommendation",
      "FGFR2::BICC1 Fusion":"Futibatinib and pemigatinib are approved therapies for this condition (EMA)",
      "TP53 p.E258* Mutation (AF 52%)":"No treatment recommendation"
    }
  },
  {
    "id": 9,
    "age": 79,
    "sex": "m",
    "diagnosis": "Salivary Duct Carcinoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "TMB 10.5 Mut/Mb",
      "HRAS p.Q61R Mutation (AF 44%)",
      "PIK3CA p.E545K Mutation (AF 39%)",
      "TP53 p.T211A Mutation (AF 60%)",
      "KMT2C p.P2493Q Mutation (AF 21%)"
    ],
    "tumor_pathogenic": [
      "TMB Tumor Mutational Burden 10.5 Mut/Mb",
      "HRAS p.Q61R Mutation (AF 44%)",
      "PIK3CA p.E545K Mutation (AF 39%)"
    ],
    "mtb_recommendations": {
      "TMB Tumor Mutational Burden 10.5 Mut/Mb":"Immunotherapy with Pembrolizumab could be explored as a treatment possibility.",
      "HRAS p.Q61R Mutation (AF 44%)":"Phase II trial, 30 patients with HNSCC, tipifarnib, ORR 55%, mPFS 5.6 months, PMID 33750196",
      "PIK3CA p.E545K Mutation (AF 39%)":"A case report describes a patient with salivary duct carcinoma (SDC) harboring a PIK3CA mutation and high androgen receptor (AR) expression who achieved a metabolic complete response (CR) with alpelisib and bicalutamide therapy for at least 12 months (m1C, PMID: 34036229, PMID: 29401002; PMID:31091374; PMID: 35133871). PIK3CA mutations may confer a higher risk of developing resistance to HRAS targeted therapies. Consider evaluation for enrolment in the CRAFT study (NCT04551521) after failure of chemotherapy, even if the patient has an HRAS mutation."
    }
  },
  {
    "id": 10,
    "age": 52,
    "sex": "f",
    "diagnosis": "Lung Adenocarcinoma",
    "stage": "IV",
    "type": "Panel",
    "germline_alteration": [],
    "tumor_alteration": [
      "EGFR p.E746_A750del Mutation (AF 50%)",
      "EGFR p.C797S Mutation (AF 29%)",
      "STK11 p.C210* Mutation (AF 39%)"
    ],
    "tumor_pathogenic": [
      "EGFR p.E746_A750del Mutation (AF 50%)",
      "EGFR p.C797S Mutation (AF 29%)",
      "STK11 p.C210* Mutation (AF 39%)"
    ],
    "mtb_recommendations": {
      "EGFR p.E746_A750del Mutation (AF 50%)":"regimen infiltration by CD8+ T cells. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762318/",
      "EGFR p.C797S Mutation (AF 29%)":"Resistance mutation to third-line TKIs. Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724843/",
      "STK11 p.C210* Mutation (AF 39%)":"The presence of a STK11 p.C210 mutation (AF 39%) suggests the possibility of primary resistance to PD-1 blockade. Source: https://meetings.asco.org/abstracts-presentations/175038"
    }
  }
]
